Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes

Prenatal Diagnosis

Volumn 28, Issue 1, 2008, Pages 28-35

  Barrett, Sandie L ^a   Bower, Carol ^b,c   Hadlow, Narelle C ^a  

^a WESTERN DIAGNOSTIC PATHOLOGY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Adverse pregnancy outcomes; First trimester screening; PAPP A; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PROTEIN A;

ARTICLE; BIRTH DEFECT; CHROMOSOME ABERRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HUMAN; LOW BIRTH WEIGHT; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ABORTION, SPONTANEOUS; ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOME ABERRATIONS; CONGENITAL ABNORMALITIES; DOWN SYNDROME; FEMALE; FETAL DEATH; GESTATIONAL AGE; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; ULTRASONOGRAPHY, PRENATAL; WESTERN AUSTRALIA;

EID: 39149097569     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1898     Document Type: Article

References (29)

1. Adekunle O, Gopee A, El-Sayed M, Thilaganathan B. 1999. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. Br J Radiol 72: 457-460.
2. Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH. 2005. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 192: 1761-1767.
3. Bower C. 1995. The value of a birth defects registry : the Western Australia experience. Perspectives in Human Biology 1: 29-36.
4. Bower C, Ryan A, Rudy E. 2001. Completeness of ascertainment of terminations of pregnancy for fetal abnormality: the effect of adding a new source of data. Teratology 63: 23-25; plus Erratum: Teratology 2001; 163: 164.
5. Bower C, Silva D, Henderson TR, Ryan A, Rudy E. 2000. Completeness of ascertainment of birth defects: the effect of adding a new source of data. J Paediatr Child Health 36: 574-576.
6. Cheng CC, Bahado-Singh RO, Chen SC, Tsai M-S. 2004. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. Int J Gynecol Obstet 84: 5-9.
7. Dugoff L, Hobbins JC, Malone FD, et al. 2004. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial). Am J Obstet Gynecol 191: 1446-1451.
8. Gee V, O'Neill M. 2002. Perinatal statistics in Western Australia, 2000. Eighteenth Annual Report of the Western Australian Midwives' Notification System. Department of Health, Perth, Western Australia.
9. Hadlow NC, Hewitt BG, Dickinson JE, Jacoby P, Bower C. 2005. Community-based screening for Down's syndrome in the first trimester using ultrasound and maternal serum biochemistry. Br J Obstet Gynaecol 112: 1561-1564.
10. Kabili G, Stricker R, Stricker R, Extermann P, Bischof P. 2004. First trimester screening for trisomy 21. Do the parameters used detect more pathologies than just Down syndrome? Eur J Obstet Gynecol Reprod Biol 114: 35-38.
11. Krantz D, Goetzl L, Simpson JL, et al. 2004. Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191: 1452-1458.
12. Kwik M, Morris J. 2003. Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome. Aust N Z J Obstet Gynaecol 43: 438-442.
13. Liu SS, Lee FK, Lee JL, et al. 2004. Pregnancy outcomes in unselected singleton pregnant women with an increased risk of first-trimester Down's syndrome. Acta Obstet Gynecol Scand 83: 1130-1134.
14. Morssink LP, Kornman LH, Hallahan TW, et al. 1998. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm deliver. Prenat Diagn 18: 147-152.
15. Ochshorn Y, Kupferminc MJ, Wolman I, Orr-Urtreger A, Jaffa AJ, Yaron Y. 2001. First trimester PAPP-A in the detection of non-Down syndrome aneuploidy. Prenat Diagn 21: 547-549.
16. O'Leary P, Breheny N, Dickinson JE, et al. 2006. First-trimester combined screening for Down syndrome and other fetal anomalies. Obstet Gynecol 107: 869-876.
17. Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. 2000. First trimester maternal serum free β human chorionic gonadotropin and pregnancy associated plasma protein A as predictors of pregnancy complications. Br J Obstet Gynaecol 107: 1265-1270.
18. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 352: 343-346.
19. Souka AP, Krampl E, Bakalis S, Heath V, Nicolaides KH. 2001. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 18: 9-17.
20. Spencer K, Nicolaides KH. 2002. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 22: 877-879.
21. Spencer K, Tul N, Nicolaides KH. 2000. Maternal serum free β-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 20: 390-394.
22. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
23. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 110: 281-286.
24. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. 1999. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19: 1035-1042.
25. Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. 2003. Predicting complications of pregnancy with first-trimester maternal serum free-βhCG, PAPP-A and inhibin-A. Prenat Diagn 23: 990-996.
26. Wapner R, Thom E, Simpson JL, et al. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349(15): 1405-1413.
27. Yaron Y, Ochshorn Y, Tsabari S, Bar Shira A. 2004. First-trimester nuchal translucency and maternal serum free β-hCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn 24: 445-450.
28. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. 2002a. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 22: 778-782.
29. Yaron Y, Ochshorn Y, Heifetz S, Lehavi O, Sapir Y, Orr-Urtreger A. 2002b. First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. Fetal Diagn Ther 17: 352-356.